Comparison of Two Different Approaches in the Surgical Treatment of Tubal Ectopic Pregnancy
Comparison of Conventional Laparoscopy and Natural Orifice Transluminal Endoscopic Surgery in the Surgical Treatment of Tubal Ectopic Pregnancy
In this study we aim to compare conventional laparoscopy and natural orifice transluminal endoscopic surgery in the surgical treatment of ectopic pregnancy.
All the patients, with an indication of surgery for ectopic pregnancy, will be asked to participate in this clinical trial.
Indication of surgery will be based on clinical findings, ultrasound scans and serum hcg levels. There will be no exclusion criteria.
Duration of surgery, successful completion of the operation, intraoperative data and postoperative data will be collected.
All the patients will be asked to fill out quality of recovery-40 (QoR-40) questionnaire and 36-item short form health survey (SF-36) before surgery.
QoR-40 questionnaire will be repeated 24 hours after surgery and repeated every 24 hours until discharge. SF-36 will be repeated at 1-month follow-up visit. Patients will be also evaluated at postoperative 3-months, and female sexual function index will be asked to be filled-out.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gokay Ozceltik
- Phone Number: +905330922020
- Email: gokayozceltik@hotmail.com
Study Locations
-
-
Izmir
-
Bornova, Izmir, Turkey, 35100
- Recruiting
- Ege University University Hospital, Department of Obstetrics and Gynecology
-
Contact:
- Gokay Ozceltik
- Phone Number: +905330922020
- Email: gokayozceltik@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults over 18 years of age,
- Diagnosis of tubal ectopic pregnancy
- Patient's preference to undergo salpingectomy
Exclusion Criteria:
- Patients with contraindication to endoscopic surgery
- Refusal to sign informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Conventional laparoscopy
In this arm, patients will be treated via conventional laparoscopy
|
Patients will undergo removal of the affected tube
|
|
Active Comparator: Transvaginal natural orifice transluminal endoscopic surgery
In this arm, patients will be treated via transvaginal natural orifice transluminal endoscopic surgery
|
Patients will undergo removal of the affected tube
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Successful completion of surgery as intended
Time Frame: Intraoperative, from the beginning to the end of surgical intervention
|
The completion of the surgery with the route planned without having to change the surgical route
|
Intraoperative, from the beginning to the end of surgical intervention
|
|
Operating time
Time Frame: Intraoperative
|
Intraoperative
|
|
|
Reoperation rate
Time Frame: During follow-up, after surgery until hcg level drops below 5 U/L, up to 1 month
|
During follow-up, after surgery until hcg level drops below 5 U/L, up to 1 month
|
|
|
Complication rate
Time Frame: During follow-up, after surgery until hcg level drops below 5 U/L, up to 1 month
|
During follow-up, after surgery until hcg level drops below 5 U/L, up to 1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Recovery-40 questionnaire
Time Frame: Preoperatively and Postoperative every 24 hours until discharge, expected to be up to 3 days following surgery
|
The Quality of Recovery 40 questionnaire will be self-administered by patients at different time points
|
Preoperatively and Postoperative every 24 hours until discharge, expected to be up to 3 days following surgery
|
|
Quality of life change
Time Frame: Preoperative, Postoperative 1-month
|
Short form 36 item health survery (SF-36) questionnaire will be self-administered by patients at different time points
|
Preoperative, Postoperative 1-month
|
|
Postoperative pain scores
Time Frame: Postoperative 2 hours, 6 hours, 12 hours, 24 hours, and every 24 hours until discharge (if the patient stays longer than 1 day at the hospital), , expected to be up to 3 days following surgery
|
Postoperative pain will be assessed on a 10-cm visual analog scale at different time points
|
Postoperative 2 hours, 6 hours, 12 hours, 24 hours, and every 24 hours until discharge (if the patient stays longer than 1 day at the hospital), , expected to be up to 3 days following surgery
|
|
Sexual function
Time Frame: Postoperative 3 months
|
Female sexual function index (FSFI) questionnaire will be self-administered by patients at postoperative 3-months
|
Postoperative 3 months
|
|
The need for additional analgesic use
Time Frame: Postoperative period until discharge, expected to be up to 3 days following surgery
|
Patients will be routinely administered pethidine hydrochloride 3x50 mg parenteral on the day of surgery.
Starting from postoperative day 1 patients will be administered paracetamol 500 mg oral upon their request.
In case of inadequate pain relief and the need for additional analgesic use will ve recorded.
|
Postoperative period until discharge, expected to be up to 3 days following surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-2.1T/40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ectopic Pregnancy
-
NCT07186127Recruiting
-
NCT01589016Completed
-
NCT07624903Not yet recruiting
-
NCT07541937Recruiting
-
NCT04951011RecruitingWoman With Tubal Ectopic Pregnancy
-
NCT01932957CompletedRuptured Ectopic Pregnancy
-
NCT01876004CompletedEctopic Pregnancy
-
NCT05498558Not yet recruitingTubal Pregnancy | Tubal-preserving Treatment of Tubal Ectopic Pregnancy | Pregnancy Preparation
-
NCT06426979Completed
-
NCT01601964CompletedComplication Following Ectopic Pregnancy
Clinical Trials on Salpingectomy
-
NCT04757922Enrolling by invitationMenopause | Salpingectomy | Tubal Ligation
-
NCT04809428CompletedSterility, Female
-
NCT07057115Recruiting
-
NCT05581654Recruiting
-
NCT02086344UnknownPelvic Pain | Adenomyosis | Uterine Fibroids | Pelvic Prolapse
-
NCT06032962CompletedOvarian Cancer Prevention
-
NCT03171467CompletedLaparoscopic Cholecystectomy | Prophylactic Salpingectomy | Opportunistic Salpingectomy
-
NCT01578759CompletedLaparoscopic Hysterectomy
-
NCT07423143Not yet recruitingMenopause | Opportunistic Salpingectomy
-
NCT04470921Active, not recruitingSTOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands (STOPOVCA)Ovarian Cancer | Risk Reduction